The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

Inclusion Criteria

• •1. Adults at least 18 years of age.
• •2. CD4 cell count of \> 400 cells.
• •3. Plasma HIV-1 RNA \< 50 copies/ml on two occasions: one within the six weeks prior to starting Baseline and the other during Baseline.
• •4. History of virologic success with suppression of HIV RNA level \< 50 copies/ml during the last nine months documented a minimum of two times during the last ten months or a minimum of three times during the last fifteen months while patient is receiving a HAART regiment. During the four months prior to starting Baseline, continuing through Baseline and the 64 week study period, the HAART regimen must remain unchanged and contain at least one of the following ten anti-retroviral drugs:
• •* Abacavir (Ziagen)
• •* Zidovudine (Retrovir) AZT
• •* Zalcitabine (Hivid) ddC
• •* Didanosine (Videx) ddl
• •* Stavudine (Zerit) d4T
• •* Efavirenz (Sustiva)
• +15 more criteria